|
CA2573505A1
|
|
N-glycosylated antibody
|
|
WO2004106917A2
|
|
Method for the selection of epitopes for immunotherapy
|
|
EP1626990A1
|
|
Immunotherapy of rectal cancer
|
|
US2007258978A1
|
|
Immunogenic recombinant antibody
|
|
ATA3832004A
|
|
Medium accessories for cell culture containing acetone
|
|
CA2494539A1
|
|
Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer
|
|
AU2003232907A8
|
|
Immunogenic, monoclonal antibody comprising at least 2 different epitopes of a tumor-associated antigen
|
|
AU2003227073A8
|
|
Method for the production of a pharmaceutical preparation by adsorption in a poorly soluble aluminum compound
|
|
ATA12172002A
|
|
Use of antibodies to tumor associated antigen
|
|
ATA9952002A
|
|
Use of an antibody directed against lewis antigene
|
|
AT500647A1
|
|
Use of a vaccinate
|
|
CZ20032573A3
|
|
Process for preparing a vaccine
|
|
MXPA03008587A
|
|
Method for producing a vaccine.
|
|
ATA8602001A
|
|
Use of polyclonal immunoglobulines
|
|
AU3900101A
|
|
Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant
|
|
WO0170272A1
|
|
Polysaccharide-polypeptide conjugate
|
|
HU0200527A2
|
|
Use of antibodies for anticancer vaccination
|
|
BR0007814A
|
|
Use of antibodies for cancer vaccination
|
|
ATA192799A
|
|
New use of antibodies as vaccine
|
